AbbVie to present new antitumor data from ADC platform

AbbVie announced that new data from its antibody-drug conjugate – ADC – platform will be showcased across three oral presentations at the upcoming ASCO Annual Meeting. ADCs are designed to deliver cancer cell death-inducing agents called ‘payloads’ to the tumor. Data from the dose-escalation and colorectal cancer – CRC – dose-expansion cohort of an ongoing first-in-human Phase 1 study of ABBV-400, a c-Met directed ADC, to be presented in an oral presentation, data show that among 122 heavily pre-treated advanced CRC patients, promising antitumor activity was observed at 2.4 and 3.0 mg/kg doses administered once every 3 weeks, with confirmed objective response rate of 18% and 24% respectively. In patients with higher c-Met expression, ORR was enriched to greater than35% at doses greater than or equal to2.4 mg/kg. The most common Grgreater than or equal to3 treatment-emergent adverse events were anemia – 35% -, neutropenia – 7% – and febrile neutropenia – 6% -. TEAEs leading to discontinuation occurred in 25 – 20.5% – patients. ABBV-400 is also being evaluated in a Phase 1b basket study in advanced solid tumors as a monotherapy and a Phase 2 study in second line metastatic CRC in combination with fluorouracil, folinic acid, and bevacizumab. In addition, early data from the monotherapy dose escalation part of a first-in-human study of ABBV-706, a directed ADC, demonstrate that overall confirmed objective response rate was 43.8%. The ongoing study is evaluating ABBV-706 as monotherapy or in combination in patients with advanced solid tumors. AbbVie will also present data from the primary analysis of the Phase 2 LUMINOSITY non-small cell lung cancer – NSCLC – trial evaluating telisotuzumab vedotin in advanced NSCLC. AbbVie previously announced positive topline results from the study in November 2023.